NSD1 Mouse anti-Human, Clone: 6C10, Invitrogen
Mouse Monoclonal Antibody
Manufacturer: Invitrogen MA518314
This antibody detects endogenous levels of NSD1 / KMT3B at a molecular weight of 300 kDa and does not cross-react with related proteins. Purity is >95% by SDS-PAGE.This gene encodes a protein containing a SET domain, 2 LXXLL motifs, 3 nuclear translocation signals (NLSs), 4 plant homeodomain (PHD) finger regions, and a proline-rich region. The encoded protein enhances androgen receptor (AR) transactivation, and this enhancement can be increased further in the presence of other androgen receptor associated coregulators. This protein may act as a nucleus-localized, basic transcriptional factor and also as a bifunctional transcriptional regulator. Mutations of this gene have been associated with Sotos syndrome and Weaver syndrome. One version of childhood acute myeloid leukemia is the result of a cryptic translocation with the breakpoints occurring within nuclear receptor-binding Su-var, enhancer of zeste, and trithorax domain protein 1 on chromosome 5 and nucleoporin, 98-kd on chromosome 11. Two transcript variants encoding distinct isoforms have been identified for this gene.
|Recombit full length human NSD1 / KMT3B|
|Antigen affinity chromatography|
|PBS with 50% glycerol and 0.02% sodium azide; pH 7.4|
|Histone-lysine N-methyltransferase, H3 lysine-36 and H4 lysine-20 specific, Androgen receptor coactivator 267 kDa protein, Androgen receptor-associated protein of 267 kDa, H3-K36-HMTase, H4-K20-HMTase, Lysine N-methyltransferase 3B, Nuclear receptor-binding SET domain-containing protein 1, NR-binding SET domain-containing protein, NSD1, ARA267, KMT3B|
|Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok